{"id":50344,"date":"2018-09-20T00:00:00","date_gmt":"2018-09-19T23:00:00","guid":{"rendered":"http:\/\/www.pcb.ub.edu\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\/"},"modified":"2018-09-20T00:00:00","modified_gmt":"2018-09-19T23:00:00","slug":"utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\/","title":{"rendered":"UTOX-PCB takes part in the Preclinonco project to develop innovative new cancer drugs"},"content":{"rendered":"

The Preclinonco project (Ref.: RTC-2017-6037-1) aims to develop new drug candidates for four types of cancer diseases for which there is no effective treatment: childhood rhabdomyosarcoma and lung, pancreatic and kidney cancers.<\/p>\n

Using molecules which have demonstrated their effectiveness in different in vitro tumour cell lines as a starting point, a study will be conducted to collect data on their effectiveness, toxicity, pharmacokinetics, pharmacodynamics and manufacturability. Based on this information, a decision will be made on which of the molecules is the best for preclinical regulatory development and, subsequently, clinical trials in humans.<\/p>\n

In addition to UTOX-PCB, the project involves the participation of the Vall d\u2019Hebr\u00f3n Research Institute (VHIR), Leitat technological centre, and Inkemia IUCT Group as coordinator. The development of technology and the investment in R&D will yield patentable technical results for the partners in the form of new products, procedures or technologies.<\/p>\n

\n\u25ba Related News [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The Unit of Experimental Toxicology and Ecotoxicology<\/a> of the Barcelona Science Park (PCB) is taking part in a consortium that aims to develop and provide preclinical checks for new candidates for first-in-class cancer drugs. The project, called Preclinonco, has just received an injection of nearly 350,000 euros from the Retos-Colaboraci\u00f3n 2017<\/a> program, promoted by the Ministry of Science, Innovation and Universities with ERDF funding.<\/p>\n

\u00a0<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-50344","post","type-post","status-publish","format-standard","category-uncategorized"],"acf":[],"yoast_head":"\nUTOX-PCB takes part in the Preclinonco project to develop innovative new cancer drugs - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UTOX-PCB takes part in the Preclinonco project to develop innovative new cancer drugs - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"The Unit of Experimental Toxicology and Ecotoxicology of the Barcelona Science Park (PCB) is taking part in a consortium that aims to develop and provide preclinical checks for new candidates for first-in-class cancer drugs. The project, called Preclinonco, has just received an injection of nearly 350,000 euros from the Retos-Colaboraci\u00f3n 2017 program, promoted by the Ministry of Science, Innovation and Universities with ERDF funding. \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-19T23:00:00+00:00\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"UTOX-PCB takes part in the Preclinonco project to develop innovative new cancer drugs\",\"datePublished\":\"2018-09-19T23:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\\\/\"},\"wordCount\":165,\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\\\/\",\"name\":\"UTOX-PCB takes part in the Preclinonco project to develop innovative new cancer drugs - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"datePublished\":\"2018-09-19T23:00:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UTOX-PCB takes part in the Preclinonco project to develop innovative new cancer drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"UTOX-PCB takes part in the Preclinonco project to develop innovative new cancer drugs - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\/","og_locale":"en_US","og_type":"article","og_title":"UTOX-PCB takes part in the Preclinonco project to develop innovative new cancer drugs - Parc Cient\u00edfic de Barcelona","og_description":"The Unit of Experimental Toxicology and Ecotoxicology of the Barcelona Science Park (PCB) is taking part in a consortium that aims to develop and provide preclinical checks for new candidates for first-in-class cancer drugs. The project, called Preclinonco, has just received an injection of nearly 350,000 euros from the Retos-Colaboraci\u00f3n 2017 program, promoted by the Ministry of Science, Innovation and Universities with ERDF funding. \u00a0","og_url":"https:\/\/www.pcb.ub.edu\/en\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2018-09-19T23:00:00+00:00","author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Written by":"adminpcb","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"UTOX-PCB takes part in the Preclinonco project to develop innovative new cancer drugs","datePublished":"2018-09-19T23:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\/"},"wordCount":165,"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\/","url":"https:\/\/www.pcb.ub.edu\/en\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\/","name":"UTOX-PCB takes part in the Preclinonco project to develop innovative new cancer drugs - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"datePublished":"2018-09-19T23:00:00+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/utox-pcb-takes-part-in-the-preclinonco-project-to-develop-innovative-new-cancer-drugs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"UTOX-PCB takes part in the Preclinonco project to develop innovative new cancer drugs"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/50344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=50344"}],"version-history":[{"count":0,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/50344\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=50344"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=50344"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=50344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}